Minocycline foam - Foamix

Drug Profile

Minocycline foam - Foamix

Alternative Names: FMX 102; FMX 103; FMX-101; FXFM-244

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Foamix
  • Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Dimethylamines; Neuroprotectants; Skin disorder therapies; Small molecules; Tetracyclines
  • Mechanism of Action Glial cell inhibitors; Interleukin 1 alpha inhibitors; Interleukin-6 modulators; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Acne vulgaris; Rosacea
  • Phase II Impetigo

Most Recent Events

  • 27 Jun 2018 Foamix Pharmaceuticals completes enrolment in its phase III extension study trials (FX2016-13) for Rosacea in the US
  • 27 Jun 2018 Foamix Pharmaceuticals completes enrolment in its phase III trials (FX2016-11;FX2016-12) for Rosacea in the US
  • 08 May 2018 Foamix Pharmaceuticals completes enrolment in the (FX2017-22) phase III trial for moderate-to-severe Acne in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top